Dr. Brown has been senior vice president of clinical development since February 2008, having served as vice president of clinical development since April 2003.  Before joining Lexicon, Dr. Brown was vice president of clinical development for Encysive Pharmaceuticals Inc. (formerly Texas Biotechnology Corporation), where he was responsible for compound development activities, including gaining marketing approval of Argatroban, a direct thrombin inhibitor for use in heparin-induced thrombocytopenia. Prior to his work at Encysive, Dr. Brown held a variety of management positions within contract research organizations. He has managed drug programs from initial regulatory filings through product approval and commercialization and has over 18 years of experience managing medical affairs, drug safety, and clinical programs in multiple therapeutic areas. Over the course of his career, Dr. Brown has conducted over 200 clinical trials as an investigator.  Dr. Brown is a fellow of the American College of Legal Medicine and serves as an adjunct faculty member at the Massachusetts General Hospital, Institute of Health Professions in Boston. He received his M.D. from Texas Tech University School of Medicine, his J.D. from the University of Texas School of Law, and his B.A. from Hendrix College.

Dr. Freiman has been medical director of drug safety since January 2008.  As a former Epidemiology Branch Chief at the U.S. Food and Drug Administration (FDA) and as a Medical Officer in the Division of Neuropharmacologic Drug Products, Dr. Freiman has more than 10 years of experience with the assessment and management of complex safety issues that arise during the course of drug development.  He received his M.P.H. from the University of Texas School of Public Health, his M.D. from New York Medical College, and his B.S. from the City College of New York.

Dr. Pappas has been senior director for clinical research since February 2008.  Following an academic clinical practice in Hepatology and Transplantation at the University of Toronto in Canada, Dr. Pappas served as the international medical director for viral hepatitis for Hoffmann-La Roche during the development of pegylated interferon therapy for chronic hepatitis C.  He was formerly the director of clinical research at St. Luke’s Texas Liver Institute, and subsequently, senior medical director for Tanox, Inc.  Prior to joining Lexicon, Dr. Pappas was director of the Texas Liver Center, Memorial Hermann Hospital and professor of medicine and director for regulatory affairs, Center for Clinical and Translational Sciences at the University of Texas Health Science Center, Houston.  Dr. Pappas has experience in drug development and clinical trial conduct both from an investigator and industry perspective.  He has published papers in the fields of medicine and law and is the recipient of numerous academic and industry awards.  Dr. Pappas is a licensed attorney in the State of Texas and a Fellow of the American College of Legal Medicine.  He continues as an adjunct faculty member in the Center for Clinical and Translational Sciences at the University of Texas Health Science Center, Houston.  He received his M.D. from Queen’s University, Canada and his J.D. from South Texas College of Law in Houston.

Mr. Frazier has been senior director of clinical operations since July 2008.  He previously served as director of clinical operations from June 2005 to July 2008.  Mr. Frazier has more than 18 years of experience in conducting Phase 1 through Phase 4 clinical trials in large pharmaceutical and biotechnology companies; working with both small molecules as well as biotherapeutics.  He has managed operations in support of global cardiovascular, HIV and central nervous system development compounds.  He has 10 years of experience in project management and directing clinical operations at DuPont Pharmaceuticals and Tanox Inc.  Mr. Frazier began his career in contract research organizations (CRO) working with Pharmaco Dynamics and Parexel International.

Ms. Clark has been senior director of regulatory affairs since July 2008.  She joined Lexicon in March 2005 as our manager of regulatory affairs and served as the director of regulatory affairs from January 2007 to July 2008.  Ms. Clark has nearly 15 years experience in regulatory affairs and clinical operations, in both start-up biotechnology and contract research organization environments.  She has had responsibility for filing numerous INDs in several therapeutic areas and direct interaction with regulatory agencies during all stages of product development.  Ms. Clark has also played an integral role in successful NDA, ANDA and PMA (device) filings, which ultimately led to product approvals.

Dr. Main has been executive vice president of pharmaceutical research since February 2007 and served as senior vice president from July 2001 to February 2007.  Dr. Main established the Medicinal Chemistry operations based in Princeton, New Jersey which are responsible for the design, synthesis, and preclinical testing of all of Lexicon’s small molecule drug candidates that may enter human clinical trials.  In addition, Dr. Main has played a key role the design and implementation of the company's scientific strategy and prioritization of Lexicon's small molecule drug discovery portfolio.  Prior to joining Lexicon, Dr. Main was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to rapidly discover new chemical entities for drug development.  Lexicon acquired Coelacanth Corporation in July 2001 to bring together the powerful biology and chemistry technologies necessary to create a revolutionary new pharmaceutical company.   Prior to Coelacanth, Dr. Main spent more than 20 years in the discovery and development of novel drugs at Novartis Pharmaceuticals Corporation where he was formerly senior vice president, U.S. Research.  Dr. Main holds a B.S. from the University of Aberdeen, Scotland, a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies with the Nobel Laureate Prof. R.B. Woodward, at the Woodward Research Institute in Basel, Switzerland.

Dr. Heydorn has been our vice president of preclinical development since June 2003.  He has more than 20 years of experience in preclinical and clinical drug development, pharmaceutical operations, project management and regulatory affairs.  Dr. Heydorn has experience with more than 25 regulatory filings and has developed an expertise in central nervous system disorders.  He has been responsible for filing new drug applications (NDAs) for candidates in depression, anxiety, Alzheimer’s disease, hypertension, and acute pain.  He has held positions with the U.S. Food and Drug Administration (FDA) as well as pharmaceutical and biotechnology companies including Marion Merrell Dow (Sanofi-Aventis), Forest Laboratories and Synaptic Pharmaceutical Corporation.  He received his B.S. in Pharmacy from the Philadelphia College of Pharmacy and Science and his Ph.D. in pharmacology from the University of Pennsylvania.

Dr. Wilson joined Lexicon in September 2003 as senior director of drug metabolism, pharmacokinetics and toxicology (DMPK).  He was promoted to his current position of vice president of DMPK in March 2005.  Prior to joining Lexicon, Dr. Wilson held senior management and leadership positions with major international pharmaceutical and life science companies including Searle, Pharmacia and Pfizer.  He is internationally recognized in drug metabolism, pharmacokinetics and toxicology and has more than 25 years of experience working on product discovery and development.  He has been involved with the registration of several successful marketed products and has extensive experience working with regulatory agencies in the United States, Europe and Asia Pacific.  Dr. Wilson has Board of Director and Scientific Advisory experience with several companies.  He is Board Certified in Toxicology and has produced more than 120 publications.  He received his Ph.D. in Drug Metabolism/PK from the University of Surrey, U.K. and his B.S. in biochemistry from the University of Surrey, U.K.  Dr. Wilson has been an invited speaker and presenter at many international conferences.